MedTrace Logo

Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial

NCT02600260 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7212

Last updated 2021-04-28

No results posted yet for this study

Summary

Hospitalization in pregnancy and childbirth greatly increases the thromboembolic risk of these patients. The application of a protocol for assessing the risk of VTE reduces mortality and morbidity of these phenomena.

Conditions

  • Thrombophilia Associated With Pregnancy
  • Perioperative/Postoperative Complications
  • Venous Thrombosis
  • Pulmonary Embolism
  • Other Specified Risk Factors in Pregnancy
  • Deep Vein Thrombosis

Interventions

DRUG

Enoxaparin

Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.

OTHER

No intervention

Hospitalized patients that score less than three are not prescribed enoxaparin.

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Venina V Barros, MD, PhD · University of Sao Paulo General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-01
Primary Completion
2019-07-31
Completion
2019-12-28

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02600260 on ClinicalTrials.gov